Results 11 to 20 of about 15,480,873 (292)

The treatment of cocaine use disorder [PDF]

open access: yesScience Advances, 2019
Current treatments for cocaine use disorder are often ineffective; new treatments are needed and are under development.
Kampman, Kyle M
openaire   +3 more sources

Ibrutinib as a potential therapeutic for cocaine use disorder [PDF]

open access: yesTranslational Psychiatry, 2021
Cocaine use presents a worldwide public health problem with high socioeconomic cost. No current pharmacologic treatments are available for cocaine use disorder (CUD) or cocaine toxicity.
Spencer B. Huggett   +7 more
doaj   +4 more sources

Clavulanic Acid Attenuated Cocaine Craving in Individuals with Cocaine Use Disorder

open access: yesPsychopharmacology Bulletin
This randomized, controlled trial examined the safety of clavulanic acid (CLAV), a GLT-1 (astrocytic glutamate transporter) modulator, in combination with intravenous cocaine to determine whether CLAV can be safely studied in outpatients with cocaine use disorder who may continue to use cocaine.
Morrison, Mary F   +6 more
openaire   +3 more sources

Detecting Small Vessel Pathology in Cocaine Use Disorder [PDF]

open access: yesFrontiers in Neuroscience, 2022
BackgroundCocaine use is associated with an increased risk of cerebrovascular accidents. Small vessel pathology has been linked to the risk of stroke in cocaine users, but can be challenging to detect on conventional magnetic resonance (MR) scans.
Marco Öchsner   +3 more
doaj   +4 more sources

Molecular genetics of cocaine use disorders in humans [PDF]

open access: yesMolecular Psychiatry, 2021
AbstractDrug addiction, one of the major health problems worldwide, is characterized by the loss of control in drug intake, craving, and withdrawal. At the individual level, drugs of abuse produce serious consequences on health and have a negative impact on the family environment and on interpersonal and work relationships.
Noèlia Fernàndez-Castillo   +3 more
openaire   +4 more sources

Subtypes of cocaine use disorder and their neurobehavioral profiles. [PDF]

open access: yesTransl Psychiatry
Cocaine Use Disorder (CUD) afflicts over 1.4 million individuals in the United States alone. However, current treatments are largely ineffective, with up to 85% returning to use long-term. We posit that addressing functional heterogeneity underlying CUD is crucial for improving treatment success.
Brucar LR   +3 more
europepmc   +3 more sources

Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review

open access: yesBrain Sciences, 2022
Background: cocaine craving is a core feature of cocaine use disorder and remains a critical challenge for abstinence and relapse prevention. This review summarizes the anti-craving efficacy of pharmacotherapies tested for cocaine use disorder, in the ...
Dângela Layne Silva Lassi   +5 more
doaj   +1 more source

Ketamine in the treatment of cocaine use disorders [PDF]

open access: yesCiência e Natura, 2022
Introduction: ketamine is a dissociative anesthetic and, recently, its antidepressant properties has been described. Besides, its safety has been proven in the treatment of Stimulant Use Disorders. Objective: to evaluate the use of ketamine in the treatment of Stimulant Use Disorders (specially cocaine and its byproducts). Methods: patient's motivation
Ronaldo Cascelli Schelb Scalla Pereira   +11 more
openaire   +1 more source

4131 Recruitment and Retention of Individuals with a Cocaine Use Disorder

open access: yesJournal of Clinical and Translational Science, 2020
OBJECTIVES/GOALS: 1) illustrate the varied challenges individuals with a cocaine use disorder experience in daily life, 2) demonstrate techniques for empathizing and building rapport with potential subjects, and 3) identify recruitment obstacles and ...
Kate Brown, Bernadette Capili
doaj   +1 more source

Agonist Medications for the Treatment of Cocaine Use Disorder [PDF]

open access: yesNeuropsychopharmacology, 2014
Cocaine addiction is a persistent and insidious public health problem (Pomara et al, 2012). Despite evidence for sustained prevalence, clinical harm, and demand for treatment, the Food and Drug Administration (FDA) has yet to approve any pharmacotherapy for its treatment.
S Stevens, Negus, Jack, Henningfield
openaire   +2 more sources

Home - About - Disclaimer - Privacy